- Published on
Infectious Disease and Microbiology - Larva migrans syndromes
Larva migrans syndromes represent a group of conditions caused by the migration of helminth larvae through human tissues, affecting the skin, internal organs, or eyes. These syndromes include cutaneous, visceral, and ocular forms, depending on where the larvae migrate. Humans are accidental hosts, and the parasites are unable to complete their life cycle, leading instead to tissue inflammation and damage.
The condition is seen worldwide but is more common in tropical and subtropical regions. Infections are particularly frequent in children, especially those under 6 years old. Cutaneous larva migrans is the most common tropical dermatosis, often acquired from contaminated beaches or soil. Visceral and ocular forms are most commonly caused by Toxocara canis and, less frequently, Toxocara cati, with a significant proportion of the population showing evidence of past infection.
Risk factors include contact with soil contaminated by dog or cat feces, poor hand hygiene, and geophagia. Children who play in contaminated environments are particularly at risk. Prevention focuses on avoiding direct contact with contaminated soil, wearing protective footwear, maintaining good hygiene, and regular deworming of pets.
The pathophysiology varies by form. In visceral larva migrans, eggs are ingested and hatch in the intestine, after which larvae migrate via the bloodstream to organs such as the liver, lungs, and central nervous system. These larvae may persist for years, causing chronic inflammation. In cutaneous larva migrans, larvae penetrate the skin but remain confined to the epidermis, migrating and forming characteristic tracks.
Cutaneous larva migrans, commonly caused by Ancylostoma braziliense, presents with intensely itchy, serpiginous, erythematous skin lesions that slowly advance over time. These lesions are most often found on the feet, legs, or areas exposed to contaminated ground. Visceral larva migrans may present with fever, fatigue, abdominal pain, cough, and hepatomegaly, while ocular larva migrans may cause visual disturbances, floaters, or even unilateral blindness due to retinal inflammation.
Physical examination findings vary with the syndrome. Cutaneous disease shows a creeping eruption on the skin, while visceral disease may show hepatomegaly, wheezing, or lymphadenopathy. Ocular disease may reveal retinal granulomas, uveitis, or optic nerve involvement on funduscopic examination.
Laboratory findings in visceral disease often include marked eosinophilia, leukocytosis, and elevated IgE levels. Serologic testing such as ELISA can support the diagnosis. Imaging studies may reveal hepatic or pulmonary lesions, while ocular disease is diagnosed primarily through ophthalmologic examination. Larvae are rarely identified directly in tissue samples.
Treatment depends on the clinical form. Cutaneous larva migrans is treated with antiparasitic agents such as albendazole or ivermectin, and symptoms usually resolve as the larvae die. Visceral larva migrans may not require treatment in mild cases, but severe disease is managed with albendazole or mebendazole. Ocular disease may also require antiparasitic therapy, often combined with corticosteroids to reduce inflammation, although treatment must be carefully managed to avoid worsening ocular damage.
Prognosis is generally good for cutaneous and most visceral cases, with spontaneous resolution common. However, ocular larva migrans carries a risk of permanent vision loss. Complications may include secondary bacterial infection in cutaneous disease, and in severe visceral cases, involvement of the brain, heart, or lungs.
- Published on
Infectious Disease and Microbiology: Intraabdominal Abscess
An intraabdominal abscess is a localized collection of microorganisms, inflammatory cells, and pus enclosed within a fibrous capsule in the abdominal cavity. These abscesses may form within the peritoneal cavity, inside abdominal organs such as the liver or spleen, or in retroperitoneal spaces. They can also extend into adjacent areas like the pelvis or psoas muscle. Based on location, intraabdominal abscesses are classified as intraperitoneal, visceral, or retroperitoneal.
Epidemiologically, intraabdominal abscesses are more common in men and typically occur between the third and fifth decades of life. Most abscesses are located in intraperitoneal or retroperitoneal spaces rather than within organs. Common causes vary by age group and condition; for example, appendicitis is a major cause in children, while postoperative complications are more common in adults. Patients with diabetes, immunosuppression, malignancy, or conditions like pancreatitis are at increased risk. Certain infections, including fungal infections such as Candida, may occur more frequently in immunocompromised individuals.
The pathophysiology usually involves the دخول of enteric organisms into the peritoneal cavity through disruption of the gastrointestinal tract, such as perforation, inflammation, trauma, or surgery. This leads to localized infection, inflammation, and abscess formation. Both aerobic and anaerobic bacteria often act synergistically. Common causative organisms include Bacteroides fragilis, Enterobacteriaceae (such as Escherichia coli), streptococci, enterococci, and sometimes fungi like Candida. The exact pathogens depend on the source and location of the infection.
Clinically, patients often present with nonspecific symptoms such as fever, abdominal pain, nausea, vomiting, malaise, and sometimes signs of sepsis. The presentation varies depending on the location of the abscess. Liver abscesses may cause right upper quadrant pain and systemic symptoms, while splenic abscesses may present with left upper quadrant pain. Perinephric abscesses often cause flank pain that may radiate to the groin. In elderly patients, fever of unknown origin may be the only presenting sign, making diagnosis challenging.
Diagnosis relies on a high index of suspicion and appropriate investigations. Laboratory findings may include leukocytosis, abnormal liver function tests, anemia, and sometimes bacteremia. Imaging plays a crucial role, with computed tomography (CT) scan being the most sensitive and widely used modality. Ultrasound is also useful, especially for liver and kidney abscesses. Definitive diagnosis is often achieved by aspiration of abscess contents for microbiological analysis, which helps guide targeted antimicrobial therapy.
Management of intraabdominal abscesses involves three key components: control of the source of infection, administration of appropriate antimicrobial therapy, and drainage of the abscess. Broad-spectrum antibiotics are initiated empirically and later tailored based on culture results. Common regimens include combinations that cover both aerobic and anaerobic organisms, such as cephalosporins with metronidazole, carbapenems, or beta-lactam/beta-lactamase inhibitor combinations. Antifungal therapy is indicated when fungal pathogens are identified.
Drainage of the abscess is essential and can be achieved either percutaneously under imaging guidance or surgically. Percutaneous drainage is preferred when feasible, but surgical intervention is required in cases where drainage is not possible, the abscess is multiloculated, or there is failure to respond to conservative treatment. Some cases, such as small or specific types of abscesses, may be managed medically under close monitoring.
Patients with severe infection may require hospitalization, fluid resuscitation, and intensive care support if septic shock develops. Ongoing care includes close monitoring, follow-up imaging, and addressing underlying conditions such as biliary disease, malignancy, or urinary tract abnormalities. Preventive strategies focus on early diagnosis and management of intraabdominal infections and prompt treatment of conditions like appendicitis or diverticulitis.
The prognosis depends on early recognition and effective management. Mortality rates remain significant, particularly for splenic and hepatic abscesses, especially if diagnosis is delayed. Prompt treatment with antibiotics and adequate drainage significantly improves outcomes.
- Published on
Infectious Disease and Microbiology: Influenza
Influenza is an acute viral respiratory infection caused by influenza viruses, typically presenting as a self-limited illness but capable of causing severe or life-threatening complications in vulnerable populations. While most healthy individuals recover fully, high-risk groups—including the elderly, young children, pregnant women, and those with chronic medical conditions—are more likely to develop complications such as pneumonia, respiratory failure, or death.
Influenza is highly prevalent worldwide, affecting approximately 5–20% of the population annually. Seasonal outbreaks occur predominantly during the winter months, often referred to as “flu season.” In the United States, influenza is responsible for tens of thousands of deaths and hundreds of thousands of hospitalizations each year. Occasionally, pandemics arise when new subtypes of influenza A viruses emerge, often due to major genetic changes, allowing rapid global spread with little preexisting immunity in the population.
Transmission occurs through respiratory droplets, direct contact with infected individuals, or contaminated surfaces. Viral shedding begins early—often within the first day of infection—and continues for about 5–10 days, though children may shed the virus longer. Preventive measures include good hand hygiene, respiratory etiquette, and especially annual vaccination. Vaccination is recommended for all individuals older than 6 months, with particular emphasis on high-risk groups. Two main vaccine types are available: inactivated vaccines given intramuscularly and live attenuated vaccines administered intranasally.
Influenza viruses are RNA viruses belonging to the Orthomyxoviridae family and are classified into types A, B, and C. Types A and B are responsible for most seasonal epidemics, while type C typically causes mild disease. Influenza A viruses are further subtyped based on hemagglutinin (HA) and neuraminidase (NA) surface proteins. Antigenic drift (small mutations) leads to seasonal variation, whereas antigenic shift (major genetic reassortment) can result in pandemics. The virus infects respiratory epithelial cells, and symptoms are largely due to the host immune response, including the release of proinflammatory cytokines, which may lead to severe complications such as cytokine storm and multiorgan failure.
Clinically, influenza is characterized by abrupt onset of fever, cough, nasal congestion, myalgia, headache, and malaise. The sudden onset of fever and cough during influenza season is highly suggestive of the disease. In some cases, especially in high-risk individuals, complications such as bacterial pneumonia may develop several days after initial symptoms, often indicated by recurrence of fever and worsening respiratory symptoms. Severe cases may involve exacerbation of underlying conditions like asthma or heart failure, as well as rare complications such as encephalitis, myocarditis, rhabdomyolysis, or shock.
Diagnosis is confirmed through laboratory testing of respiratory specimens. Reverse transcription polymerase chain reaction (RT-PCR) is the most sensitive and specific test and provides rapid results. Rapid antigen tests are also available but are less sensitive, especially in adults. Imaging such as chest X-ray may be necessary in severe cases to assess for pneumonia or other complications.
Treatment includes antiviral medications and supportive care. Neuraminidase inhibitors such as Oseltamivir and Zanamivir are effective against both influenza A and B and are most beneficial when started within 48 hours of symptom onset. They are especially recommended for high-risk patients or those with severe disease. Older drugs such as amantadine and rimantadine are less commonly used due to resistance. Supportive care includes rest, hydration, and management of symptoms.
In hospitalized patients, severe influenza may require intensive care support, including oxygen therapy, mechanical ventilation, or extracorporeal membrane oxygenation in cases of respiratory failure. Early antiviral treatment is recommended for hospitalized patients regardless of the duration of symptoms.
The prognosis for most individuals is good, with complete recovery expected. However, influenza can lead to serious complications, particularly in high-risk groups. These include bacterial pneumonia (commonly due to Streptococcus pneumoniae), acute respiratory distress syndrome (ARDS), myocarditis, and neurologic complications such as encephalopathy or Guillain–Barré syndrome. Vaccination and early treatment remain key strategies in reducing morbidity and mortality associated with influenza.
- Published on
Infectious Disease and Microbiology: Infectious Mononucleosis
Infectious mononucleosis (IM), also known as glandular fever, is a common self-limiting clinical syndrome caused primarily by Epstein–Barr virus. It is characterized by acute onset of fever, sore throat, lymphadenopathy, and atypical lymphocytosis. EBV is transmitted mainly through saliva, which is why the illness is often called the “kissing disease.” After infection, the virus persists lifelong in the host.
IM is common worldwide. In industrialized countries, EBV infection often occurs either in early childhood, when it is usually asymptomatic, or in late adolescence, when it is more likely to cause symptomatic mononucleosis. By adulthood, 90–95% of people have evidence of prior EBV infection. Risk factors include close contact with an infected person and immunosuppression, especially in transplant recipients. In rare cases, certain inherited immune defects can lead to severe, even life-threatening EBV infection.
The pathophysiology begins when EBV infects the oropharyngeal epithelium and then B lymphocytes. The immune response, especially proliferation of cytotoxic CD8+ T lymphocytes, is responsible for much of the clinical syndrome. These activated lymphocytes appear as atypical lymphocytes on the blood smear. Although the immune response controls the primary infection, EBV remains latent for life.
Clinically, young children are often asymptomatic or have only mild illness. In adolescents and young adults, the disease usually begins with fatigue, malaise, and myalgias, followed by fever and sore throat. Common symptoms include fever, sore throat, malaise, headache, anorexia, myalgias, and sometimes abdominal pain, nausea, or vomiting. On examination, patients commonly have cervical lymphadenopathy, pharyngitis or tonsillitis, splenomegaly, and sometimes hepatomegaly. Less common findings include palatal petechiae, periorbital edema, rash, and jaundice. A maculopapular rash may occur, especially after exposure to ampicillin or amoxicillin.
Diagnosis is usually supported by laboratory findings. Atypical lymphocytosis and relative or absolute lymphocytosis are common. Mild thrombocytopenia and elevated liver enzymes may also be present. Heterophile antibody tests such as the Monospot are widely used and are fairly sensitive and specific in symptomatic patients, although they may be negative early in illness or in young children. EBV-specific serology, including viral capsid antigen and EBV nuclear antigen antibodies, can help confirm the diagnosis when needed. Ultrasound may be used to assess splenomegaly, especially in athletes.
Treatment is mainly supportive. Most patients only need rest, fluids, and symptom relief with acetaminophen or nonsteroidal anti-inflammatory drugs. Corticosteroids are reserved for severe complications such as impending airway obstruction, severe thrombocytopenia, hemolytic anemia, myocarditis, pericarditis, or neurologic complications. Patients should avoid contact sports and strenuous physical activity for at least 3–4 weeks, or longer if splenomegaly persists, because of the risk of splenic rupture. Beta-lactam antibiotics such as ampicillin and amoxicillin should be avoided unless clearly indicated for another reason.
The prognosis is generally excellent, and most cases resolve within 1–2 weeks. However, fatigue may persist for weeks or even months in some patients. Complications are uncommon but may include autoimmune hemolytic anemia, thrombocytopenia, airway obstruction, hepatitis, myocarditis, pericarditis, neurologic syndromes, pneumonia, splenic rupture, and lymphoproliferative disorders in susceptible individuals.
- Published on
Infectious Disease and Microbiology: HIV Infection
Human immunodeficiency virus (HIV) infection is a chronic viral disease that progressively impairs the immune system, primarily through destruction and dysfunction of CD4+ T lymphocytes. Without treatment, it can lead to acquired immunodeficiency syndrome (AIDS), the advanced stage of infection characterized by severe immunosuppression, opportunistic infections, malignancies, and death. HIV-1 is the predominant type worldwide, while HIV-2 is found mainly in West Africa and generally causes slower disease progression.
HIV remains a major global health problem, affecting millions of individuals worldwide. In the United States alone, more than one million people are living with HIV, with tens of thousands of new infections occurring annually. Transmission occurs through sexual contact, blood exposure such as needle-sharing or occupational exposure, and mother-to-child transmission during pregnancy, delivery, or breastfeeding. The risk of transmission varies by route, with blood exposure and receptive anal intercourse carrying higher risks than other exposures. Advances in antiretroviral therapy (ART) and perinatal management have markedly reduced maternal–fetal transmission.
The virus is a retrovirus of the lentivirus family. It binds to CD4 receptors and co-receptors on host lymphocytes, enters the cell, and uses reverse transcriptase to convert viral RNA into DNA. This viral DNA integrates into the host genome, allowing lifelong infection. Subsequent activation of infected cells leads to production of new viral particles, which destroy CD4 cells and gradually weaken cellular immunity. This immune dysfunction predisposes patients to a wide range of infectious and noninfectious complications.
Clinically, HIV infection progresses through several stages. Acute HIV infection may occur within weeks of transmission and often presents with a nonspecific viral syndrome including fever, pharyngitis, rash, myalgias, lymphadenopathy, diarrhea, and headache. This is followed by an asymptomatic phase that may last many years, during which viral replication continues and CD4 counts slowly decline. Symptomatic HIV infection develops as immunosuppression worsens and may include recurrent mucocutaneous infections, weight loss, fevers, and eventually opportunistic infections such as Pneumocystis jirovecii pneumonia, cryptococcal meningitis, toxoplasmosis, cytomegalovirus disease, and Mycobacterium avium complex infection. HIV is also associated with malignancies such as Kaposi sarcoma, lymphoma, cervical cancer, and neurologic complications including HIV-associated neurocognitive disorder.
Diagnosis begins with screening using highly sensitive HIV antibody tests, followed by confirmatory testing. In suspected acute HIV infection, HIV RNA testing is essential because antibody tests may still be negative during early infection. Once diagnosis is confirmed, baseline evaluation includes CD4 count, HIV viral load, resistance genotype, complete blood count, renal and liver function tests, and screening for co-infections such as hepatitis A, B, and C, syphilis, tuberculosis, toxoplasmosis, cytomegalovirus, and varicella zoster. These tests help assess disease stage, identify treatment needs, and detect concurrent infections.
Treatment with antiretroviral therapy is the cornerstone of HIV management. The goals of ART are to suppress plasma HIV RNA to undetectable levels, preserve or restore immune function, reduce HIV-related complications, and prevent transmission. Standard treatment consists of combination therapy using multiple drug classes, commonly two nucleos(t)ide reverse transcriptase inhibitors together with either a non-nucleoside reverse transcriptase inhibitor, a protease inhibitor, or an integrase strand transfer inhibitor. Choice of regimen depends on drug resistance, side effects, pill burden, co-morbidities, pregnancy considerations, and potential drug interactions. ART is generally lifelong, and adherence is critical to prevent virologic failure and resistance.
Prevention of HIV includes condom use, safe blood practices, clean needle access, screening of blood products, and routine testing, especially in pregnancy and high-risk populations. Post-exposure prophylaxis should be started as soon as possible after significant occupational or non-occupational exposure, ideally within hours and no later than 72 hours, and continued for four weeks. Pre-exposure prophylaxis has also become an important preventive strategy for individuals at substantial risk.
Ongoing care requires regular monitoring of viral load, CD4 count, medication toxicity, cardiovascular risk factors, and co-infections. Patients with advanced immunosuppression require prophylaxis against opportunistic infections, such as trimethoprim-sulfamethoxazole for Pneumocystis and toxoplasmosis, and azithromycin for Mycobacterium avium complex when indicated. Vaccination, cancer screening, and management of long-term complications are also essential parts of care.
The prognosis of HIV infection has improved dramatically with effective ART. Many patients who are diagnosed early and remain adherent to treatment can achieve near-normal life expectancy. However, treatment failure may occur due to poor adherence or drug resistance, leading to virologic, immunologic, and clinical decline. Without treatment, HIV infection remains a progressive and often fatal disease.
- Published on
Infectious Disease and Microbiology: Histoplasmosis
Histoplasmosis is an inhalation-acquired fungal infection primarily affecting the lungs and caused by the dimorphic fungus Histoplasma capsulatum. It is an endemic mycosis, meaning it occurs in specific geographic regions, and infection typically follows inhalation of fungal spores from contaminated environments such as soil enriched with bird or bat droppings.
Epidemiologically, histoplasmosis is most common in areas such as the Ohio and Mississippi River valleys in the United States, with hundreds of thousands of infections occurring annually. Although both sexes are equally exposed, disseminated disease is more common in males. Individuals at highest risk include infants, older adults, and especially immunocompromised patients, such as those with HIV/AIDS, malignancies, organ transplants, or those receiving immunosuppressive therapies.
The pathophysiology begins when microconidia (infectious spores) are inhaled into the lungs. Inside the host, the organism converts from its mold form to a yeast form and multiplies within macrophages. This intracellular survival allows the fungus to spread through the reticuloendothelial system. While most infections remain localized and asymptomatic, impaired immunity can lead to widespread dissemination affecting multiple organs.
Clinically, histoplasmosis presents in several forms. Acute pulmonary histoplasmosis is often asymptomatic or presents as a mild flu-like illness with fever, cough, chest pain, and malaise. Chronic pulmonary histoplasmosis, typically seen in older individuals with underlying lung disease, resembles tuberculosis with symptoms such as chronic cough, weight loss, night sweats, and hemoptysis. Disseminated histoplasmosis is the most severe form, particularly in immunocompromised patients, and may involve fever, hepatosplenomegaly, skin lesions, adrenal insufficiency, or even central nervous system involvement.
Physical examination findings vary depending on the form of disease but may include enlarged liver and spleen, skin eruptions, or mucosal ulcers in disseminated disease. Pulmonary findings such as crackles or signs of consolidation may also be present. In some cases, complications such as mediastinal fibrosis or pericarditis can occur due to lymph node involvement.
Diagnosis is established through a combination of laboratory and imaging studies. Detection of Histoplasma antigen in urine or serum is highly sensitive, especially in disseminated disease. Fungal cultures can confirm the diagnosis but may take several weeks. Serologic tests, PCR, and histopathological examination of tissue samples showing granulomas with yeast forms are also useful. Imaging studies, such as chest X-rays or CT scans, may reveal pulmonary infiltrates, nodules, calcifications, or lymphadenopathy.
Treatment depends on disease severity. Mild acute pulmonary histoplasmosis often requires no treatment and resolves spontaneously. More severe or persistent cases are treated with antifungal agents such as itraconazole. Severe or disseminated disease requires initial therapy with amphotericin B followed by prolonged itraconazole therapy. Immunocompromised patients may require long-term suppressive therapy to prevent relapse.
The prognosis of histoplasmosis is generally good in mild cases but can be life-threatening in disseminated disease, particularly in immunosuppressed individuals. Complications include chronic lung damage, adrenal insufficiency, mediastinal fibrosis, and, in severe cases, respiratory failure or death. Early recognition and appropriate antifungal therapy are critical in improving outcomes.
- Published on
Infectious Disease and Microbiology: Herpes Zoster (Shingles)
Herpes zoster, commonly known as shingles, is a localized skin and nerve infection caused by reactivation of the Varicella zoster virus, the same virus responsible for chickenpox. After a primary infection, the virus remains dormant in sensory nerve ganglia for years. Reactivation later in life leads to herpes zoster, typically presenting as a painful, vesicular rash confined to a specific dermatome.
Epidemiologically, herpes zoster occurs worldwide and affects approximately 20% of individuals during their lifetime. The incidence increases significantly with age, particularly in those over 50 years. Nearly 90% of adults have evidence of prior VZV infection, placing them at risk for reactivation. Immunocompromised individuals—such as those with HIV infection, malignancies, or those receiving immunosuppressive therapy—are at particularly high risk and may develop more severe or disseminated disease.
The pathophysiology involves reactivation of latent virus within dorsal root or cranial nerve ganglia. The virus travels along sensory nerves to the skin, producing inflammation and the characteristic painful rash. The exact triggers for reactivation are not fully understood but are strongly associated with declining cell-mediated immunity, especially in aging or immunosuppressed individuals.
Clinically, patients typically present with localized pain, burning, or tingling in a dermatomal distribution, often preceding the rash by a few days. This is followed by the appearance of grouped vesicles on an erythematous base, usually confined to one side of the body. The thoracic and lumbar dermatomes are most commonly affected. Involvement of the trigeminal nerve may lead to ocular complications (herpes zoster ophthalmicus), while involvement of the geniculate ganglion can result in Ramsay Hunt syndrome, characterized by ear lesions and facial paralysis.
Diagnosis is primarily clinical, based on the typical unilateral dermatomal rash and associated pain. Laboratory tests such as PCR or serology can confirm the diagnosis but are rarely necessary in routine cases. Imaging or lumbar puncture may be required if central nervous system involvement is suspected.
Treatment focuses on antiviral therapy and pain management. First-line therapy includes oral acyclovir, while alternatives such as valacyclovir or famciclovir offer improved dosing convenience. In severe cases or immunocompromised patients, intravenous antivirals may be required. Adjunctive therapies, including analgesics and sometimes corticosteroids, may help reduce acute symptoms, although steroids do not prevent long-term complications.
The prognosis is generally good in immunocompetent individuals, but complications are not uncommon. The most significant is postherpetic neuralgia, a chronic pain condition that can persist long after the rash resolves, particularly in older adults. Other complications include secondary bacterial infection, ocular damage potentially leading to blindness, and, in severe cases, systemic involvement such as pneumonitis, hepatitis, or central nervous system disease.
Prevention includes vaccination against VZV, which reduces both the incidence of herpes zoster and the risk of postherpetic neuralgia. In high-risk individuals, prophylactic antivirals or immunoglobulin may be used following exposure.
- Published on
Infectious Disease and Microbiology: Hemolytic–Uremic Syndrome (HUS)
Hemolytic–uremic syndrome (HUS) is a serious clinical condition characterized by a triad of acute renal failure, microangiopathic hemolytic anemia, and thrombocytopenia. It is most commonly associated with infection by Shiga toxin–producing bacteria, particularly Escherichia coli O157:H7 (EHEC). HUS primarily affects young children but can occur at any age and is a major cause of acute kidney injury in pediatric populations.
Epidemiologically, HUS is closely linked to infections caused by enterohemorrhagic E. coli, with an incidence of approximately 1–5 cases per 100,000 people annually in industrialized countries. The infection is more common in children under 5 years old and tends to peak during warmer months, particularly from June to September. Although many individuals infected with EHEC develop only mild gastrointestinal symptoms, about 8% of cases during outbreaks progress to HUS, especially in vulnerable populations such as young children and the elderly.
Transmission is primarily food-borne and is strongly associated with the consumption of undercooked ground beef, unpasteurized milk, contaminated water, and fresh produce such as apples or melons. Cattle serve as the main reservoir, often carrying the organism asymptomatically in their intestines. Infection can also spread through person-to-person contact, particularly in settings such as daycare centers and nursing homes. Proper food handling, cooking, and hygiene practices are essential preventive measures.
The pathophysiology of HUS involves the production of Shiga-like toxin by EHEC. This toxin damages endothelial cells, particularly in the kidneys, leading to inflammation, platelet activation, and formation of microthrombi in small blood vessels. These processes result in mechanical destruction of red blood cells (hemolysis), platelet consumption (thrombocytopenia), and reduced renal perfusion, ultimately causing acute kidney injury.
Clinically, infection typically begins with abdominal cramps and watery diarrhea, which progresses within 24 hours to bloody diarrhea in most patients. Nausea and vomiting are common, while fever is usually absent or mild. As HUS develops, signs such as decreased urine output (oliguria), pallor from anemia, and fatigue become evident. The drop in hematocrit and platelet count are early laboratory indicators of disease progression.
Diagnosis is based on clinical findings and laboratory confirmation. Stool cultures using special media are required to identify EHEC, as routine cultures may miss the organism. Laboratory findings in HUS include anemia with fragmented red blood cells (schistocytes), elevated lactate dehydrogenase (LDH), low haptoglobin, thrombocytopenia, and elevated creatinine levels indicating renal impairment. Urinalysis may show hematuria and proteinuria.
Management of HUS is primarily supportive. Antibiotics are generally not recommended in EHEC infections, as they may increase toxin release and worsen the condition. Similarly, antimotility agents should be avoided because they can enhance toxin absorption. Treatment focuses on maintaining fluid and electrolyte balance, managing renal failure with dialysis if necessary, and providing blood transfusions when indicated. In severe cases, plasmapheresis may be used.
The prognosis of HUS varies depending on severity and patient factors. Despite advances in supportive care, mortality rates range from 5% to 20%, with higher rates in older adults. Among survivors, long-term complications are common, including chronic kidney disease and hypertension, with many patients eventually requiring dialysis or kidney transplantation.
Complications of HUS include severe anemia, thrombocytopenia, electrolyte disturbances, rhabdomyolysis, and permanent renal damage. Additionally, EHEC infection itself may cause hemorrhagic colitis or, less commonly, conditions such as thrombotic thrombocytopenic purpura. Early recognition and supportive management are critical to improving outcomes.
- Published on
Infectious Disease and Microbiology: Hantavirus Pulmonary Syndrome (HPS)
Hantavirus pulmonary syndrome (HPS) is a severe and life-threatening cardiopulmonary disease caused by hantaviruses, most commonly the Sin Nombre virus in North America. First recognized in 1993 in the southwestern United States, the disease is associated with a high mortality rate and rapid clinical deterioration. It primarily affects previously healthy individuals who are exposed to infected rodents.
Epidemiologically, HPS is rare but has been reported in multiple regions across the Americas. Its occurrence is closely linked to the population dynamics of rodents, particularly deer mice and other species such as cotton rats and white-footed mice. Human infection typically results from inhalation of aerosolized particles contaminated with rodent urine, feces, or saliva. Individuals at higher risk include farmers, construction workers, campers, and those cleaning rodent-infested buildings. Although person-to-person transmission is extremely uncommon, it has been reported in certain regions with specific strains such as the Andes virus.
The pathophysiology of HPS involves viral infection of endothelial cells, especially within the lungs, leading to increased vascular permeability. This results in capillary leak syndrome, pulmonary edema, and impaired oxygen exchange. The disease is driven largely by the host immune response rather than direct viral destruction of tissues, leading to pneumonitis, shock, and respiratory failure.
Clinically, the illness begins with a prodromal phase lasting several days, characterized by nonspecific symptoms such as fever, myalgia, fatigue, headache, and sometimes gastrointestinal complaints. This is followed by an abrupt cardiopulmonary phase marked by cough and rapidly progressive shortness of breath, often leading to respiratory failure within a short time. Physical findings include tachypnea, hypoxia, pulmonary crackles, and signs of circulatory shock. Death may occur due to severe hypoxia, shock, or cardiac arrhythmias.
Laboratory evaluation typically reveals leukocytosis with a left shift, thrombocytopenia, hemoconcentration, and atypical lymphocytes. Elevated liver enzymes, creatine phosphokinase, and lactate dehydrogenase are also common. Imaging studies such as chest X-ray or CT scan demonstrate interstitial infiltrates, pulmonary edema, and pleural effusions. Diagnosis is confirmed through serologic testing detecting hantavirus-specific IgM or rising IgG titers, PCR identification of viral RNA, or immunohistochemical detection of viral antigens in tissue samples.
Management of HPS is primarily supportive, as no proven antiviral therapy exists. Patients often require hospitalization and close monitoring, with many needing intensive care, oxygen supplementation, or mechanical ventilation. Broad-spectrum antibiotics are usually started initially until other causes of severe pneumonia are excluded. In critical cases, advanced supportive therapies such as extracorporeal membrane oxygenation (ECMO) may be employed. Prevention relies on minimizing exposure to rodents and their excreta, as no vaccine is currently available.
The prognosis of HPS is guarded, with mortality rates ranging from 35% to 40%, especially in patients with severe disease. Early recognition and aggressive supportive care improve survival. Major complications include acute respiratory distress syndrome, myocardial dysfunction, shock, and death.
- Published on
Infectious Disease and Microbiology: Helicobacter pylori Infection
Helicobacter pylori infection is a common chronic bacterial infection of the stomach and is the leading cause of gastritis, peptic ulcer disease, and an important risk factor for gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma. It is a gram-negative, spiral-shaped, microaerophilic organism that colonizes the gastric mucosa and can persist for decades if untreated. Although many infected individuals remain asymptomatic, the organism is associated with significant gastrointestinal morbidity.
Epidemiologically, H. pylori infects more than half of the global population, with a much higher prevalence in developing countries compared to industrialized nations. In developed regions such as the United States, prevalence is approximately 30%, increasing with age, whereas in developing countries it may reach up to 80%, often beginning in childhood. Risk factors are largely related to socioeconomic conditions, including poor sanitation, crowded living environments, and lack of access to clean water. Infection is usually acquired in early childhood and spreads primarily through person-to-person transmission via oral–oral or fecal–oral routes.
The pathophysiology of H. pylori infection is centered on its ability to survive in the acidic gastric environment through the production of urease, which converts urea into ammonia, thereby neutralizing gastric acid. The bacterium colonizes the gastric mucosa, leading to chronic active gastritis characterized by inflammatory cell infiltration. Over time, this can result in mucosal damage, ulcer formation, intestinal metaplasia, and in some cases, malignant transformation. Certain bacterial strains, such as those expressing cytotoxin-associated gene A (cagA), and host genetic factors increase the risk of severe disease.
Clinically, most patients with H. pylori infection are asymptomatic. When symptoms occur, they are usually related to dyspepsia, including upper abdominal pain, bloating, early satiety, and nausea. Alarm features such as weight loss, gastrointestinal bleeding, anemia, persistent vomiting, or progressive dysphagia raise concern for more serious conditions such as peptic ulcer disease or malignancy and require prompt evaluation.
Diagnosis can be made using invasive or non-invasive methods. Non-invasive tests include the urea breath test and fecal antigen test, both of which have high sensitivity and specificity and are commonly used for both diagnosis and confirmation of eradication. Serologic testing is less reliable due to its inability to distinguish between active and past infection. Invasive testing involves endoscopy with biopsy for urease testing, histology, or culture and is recommended in older patients or those with alarm symptoms. Certain medications, such as proton pump inhibitors and antibiotics, may reduce test accuracy and should be discontinued prior to testing.
Treatment of H. pylori infection involves combination therapy to achieve eradication and prevent complications. First-line regimens typically include a proton pump inhibitor combined with antibiotics such as clarithromycin and amoxicillin or metronidazole (triple therapy), or a bismuth-based quadruple regimen including bismuth, tetracycline, metronidazole, and acid suppression therapy. Treatment duration ranges from 10 to 14 days, and eradication rates are influenced by antibiotic resistance patterns. Second-line therapies include alternative antibiotic combinations such as levofloxacin-based regimens.
Follow-up is important to confirm eradication, particularly in patients with persistent symptoms, ulcers, MALT lymphoma, or a history of gastric cancer. Non-invasive tests such as the urea breath test or fecal antigen test are preferred for this purpose. Patient education should emphasize adherence to therapy, as incomplete treatment contributes to treatment failure and resistance.
The prognosis is generally favorable with successful eradication, which significantly reduces the risk of ulcer recurrence and complications. However, untreated infection may lead to chronic gastritis, peptic ulcer disease, gastric adenocarcinoma, and MALT lymphoma. Recurrence rates are low in developed countries but higher in areas with poor sanitation. Common treatment-related side effects include gastrointestinal upset and taste disturbances.
